This market
research report presents a comprehensive segmentation of the global
immunotherapy drugs market by type of immunotherapy (mAbs, vaccines, immune
checkpoint inhibitors, non-specific immunotherapies, and others), by therapy
area (oncology, infectious disease, autoimmune and inflammatory disorders,
respiratory diseases, and others), and by geography (the Americas, APAC, and
EMEA). Key vendors are AbbVie, Amgen, Bristol-Myers Squibb, F.Hoffmann-La
Roche, Johnson & Johnson, and Merck.
Overview of the global immunotherapy drugs
market
The market research analyst predicts that the global immunotherapy drugs market will grow at a steady CAGR of close to 12% by 2020. During a rise in cancer and a number of autoimmune diseases, the need for immunotherapy drugs is on the rise. Furthermore, with the increasing demand for mAbs, the market for immunotherapy drugs will have a positive outlook until the end of the forecast period. mAbs have a high affinity for specific disease cells and areas that need treatment. Consequently, they can be used for therapies like radio immunotherapy and antibody-directed enzyme prodrug therapy. The augmented usage of these antibodies in drug development will help to bolster the market’s revenue generating capacity over the course of the next four years.
The market research analyst predicts that the global immunotherapy drugs market will grow at a steady CAGR of close to 12% by 2020. During a rise in cancer and a number of autoimmune diseases, the need for immunotherapy drugs is on the rise. Furthermore, with the increasing demand for mAbs, the market for immunotherapy drugs will have a positive outlook until the end of the forecast period. mAbs have a high affinity for specific disease cells and areas that need treatment. Consequently, they can be used for therapies like radio immunotherapy and antibody-directed enzyme prodrug therapy. The augmented usage of these antibodies in drug development will help to bolster the market’s revenue generating capacity over the course of the next four years.
Complete Report Details Available @ https://www.wiseguyreports.com/reports/global-immunotherapy-drugs-market-2016-2020
.
An important factor
impelling the prospects for growth in this market is the emergence of
biosimilars. Unlike generic drugs, which have active pharmaceutical ingredients
similar to original drugs, biosimilars are almost identical to their originator
biologic compounds. Since biosimilars help to make treatments more accessible
to patients and are less expensive than biologics, their sale among the end
users is anticipated to increase significantly over the next few years.
Segmentation by type of immunotherapy and
analysis of the immunotherapy drugs market
- mAbs
- Vaccines
- Immune checkpoint inhibitors
- Non-specific immunotherapies
- mAbs
- Vaccines
- Immune checkpoint inhibitors
- Non-specific immunotherapies
During 2015, the
mAbs segment dominated this market and accounted for an impressive market share
of nearly 61%. The development of new drugs and the entry of new molecules like
zanolimumab, elotuzumab, obinutuzumab, and onartuzumab into the market will aid
in the growth of this market segment during the forecast period.
Geographical segmentation and analysis of the
immunotherapy drugs market
- Americas
- APAC
- EMEA
- Americas
- APAC
- EMEA
Purchase
a 1-User License Copy @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=379026
.
The Americas dominated the global market with over 50% market share in
2015. The market is flourishing in this region due to the higher incidences of
cancer, infectious diseases, and autoimmune diseases in the US. Additionally,
factors such as the high affordability of therapies due to the presence of
well-structured reimbursement plans will also spur the prospects for market
growth until 2020.
Competitive
landscape and key vendors
The global market for immunotherapy drugs is highly competitive due to the presence of a number of large and small vendors. Many of these vendors have a huge global presence and enter into strategic alliances to aid in the manufacture and marketing of essential drugs. Safety and effectiveness of drugs are key factors, which will give vendors an edge in the marketplace.
The global market for immunotherapy drugs is highly competitive due to the presence of a number of large and small vendors. Many of these vendors have a huge global presence and enter into strategic alliances to aid in the manufacture and marketing of essential drugs. Safety and effectiveness of drugs are key factors, which will give vendors an edge in the marketplace.
Key vendors in
this market are -
·
AbbVie
·
Amgen
·
Bristol-Myers Squibb
·
F.Hoffmann-La Roche
·
Johnson & Johnson
·
Merck
Inquire for more
information @ https://www.wiseguyreports.com/sample_request/telehealth-global-market-trends-regulatory-landscape-and-operational-strategies
.
Other
prominent vendors are AB Science. Ablynx, Acorda
Therapeutics, ADC Therapeutics, Aduro Biotech, Advantagene, Advaxis, Agensys,
Agenus, Alder Biopharmaceuticals, AlphaVax, Altor BioScience, Antares Pharma,
Antigen Express, Argos Therapeutics, Astellas Pharma, AstraZeneca, AVAX
Technologies, Bavarian Nordic, Baxter, Bayer, Biogen, Biotech Pharmaceutical,
Biothera, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celldex
Therapeutics, Celltrion, Cel-Sci, ChemoCentryx, Chugai Pharmaceutical, Coherus
BioSciences, CTI BioPharma, CureVac, Daiichi Sankyo, Eisai, Eli Lilly, Fortress
Biotech, Galena Biopharma, Genexine, Genmab, Gilead Sciences, GSK, GlobeImmune,
Gradalis, Heat Biologics, Hospira, Idera, Inmatics, ImmunoCellular
Therapeutics, Immunomedics, ImmuPharma, Immutep, Incyte, Inovio
Pharmaceuticals, Intas Pharmaceuticals, Invion, ISA Pharmaceuticals, Janssen
Biotech, Juvaris Biotherapeutics, KaloBios Pharmaceuticals, Kyowa Hakko Kirin,
Lexicon Pharmaceuticals, MedImmune, Morphotek, Neovii Biotech, Northwest
Biotherapeutics, Novartis, NovaRx, Novo Nordisk, OncoMed Pharmaceuticals,
Oncothyreon, Oncovir, Opexa Therapeutics, Oxford BioMedica, Pfizer, Prima
BioMed, Principia, Progenics, Provectus Biopharmaceuticals, Regeneron, Sandoz,
Sanofi, Santarus, Seattle Genetics, Sotio, Spectrum Pharmaceuticals, Takeda, TG
Therapeutics, Transgene, UbiVac, UCB, Vaccinex, Vaccinogen, Vaxon Biotech,
Vertex Pharmaceuticals, Vical, Vitae Pharmaceuticals, and XBiotech.
